CervoMed
CRVO | NASDAQ
$1.67
-$0.02 (-1.18%)
At close: Nov 16, 2026, 4:00 PM ET
$1.65
-$0.02 (-1.16%)
After-hours:
Nov 16, 2026, 7:58 PM ET
-1.18%
(1D)No price chart data available for 1D timeframe.
Rating
27.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #863/1021 (Top 85%)
Key Statistics
Market Data
Market Cap $25.26M
1D Range
1.65 1.90
52W Range
1.37 9.94
Valuation (TTM)
PE -0.61
PB 1.46
EV/EBITDA -0.20
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $7.00
Cash Flow
FCF Yield -105.2%
SBC Adj. FCF Yield -109.3%
SBC Impact -3.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y 0.0% |
50.0%
Dil EPS 3Y | 5Y -22.9% |
40.5%
FCF 3Y | 5Y -37.4% |
-44.7%
Returns
ROA -133.7%
ROE -164.9%
ROIC -168.4%
Financial Health
Net Cash
$19.6M
Current Ratio 5.37
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an o...
Sector Healthcare
Industry Biotechnology
Employees 15
IPO Date May 23, 2008
Website www.cervomed.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$7.00
Upside
+319.16%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CRVO